<DOC>
	<DOCNO>NCT01930396</DOCNO>
	<brief_summary>The HEMO-TIN trial design look safety ( bleed risk ) effectiveness ( clot risk ) tinzaparin compare unfractionated heparin anticoagulation hemodialysis patient .</brief_summary>
	<brief_title>Use Tinzaparin Anticoagulation Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>Age &gt; = 18 year End stage renal disease maintain outpatient hemodialysis &gt; = 3 month Frequency hemodialysis : 3 time per week Anticoagulation unfractionated heparin protocol least 4 week Patient legal guardian able provide write consent Baseline INR &lt; = 1.3 Baseline platelet count &gt; = 80,000 x 10^9/L Therapeutic systemic anticoagulation Clinically apparent bleeding last 2 month High risk bleeding Planned major surgery next 4 month Major surgery past 48 hour Pregnant lactate Child bear potential Allergy/intolerance heparin history heparin induce thrombocytopenia Current participation relate randomized drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Tinzaparin</keyword>
	<keyword>Unfractionated Heparin</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>